Indexed with PubMed and Science Citation Index (E) 
Users online: 2324 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
 # Next article
 # Previous article 
 # Table of Contents
 Resource links
 #  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
 #  Article in PDF (25 KB)
 #  Citation Manager
 #  Access Statistics
 #  Reader Comments
 #  Email Alert *
 #  Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded321    
    Comments [Add]    

Recommend this journal

Year : 2003  |  Volume : 69  |  Issue : 5  |  Page : 355-356

Safety of dermatologic agents in pregnancy

Department of Dermatology, KEM Hospital and Seth GS Medical College, Mumbai - 400012

Correspondence Address:
Department of Dermatology, KEM Hospital and Seth GS Medical College, Mumbai - 400012

How to cite this article:
Pande S, Kharkar V. Safety of dermatologic agents in pregnancy. Indian J Dermatol Venereol Leprol 2003;69:355-6

How to cite this URL:
Pande S, Kharkar V. Safety of dermatologic agents in pregnancy. Indian J Dermatol Venereol Leprol [serial online] 2003 [cited 2020 Aug 13];69:355-6. Available from:

Dermatologists need to be the familiar with the potential of medications to cause harm to the fetus or the mother. Moreover, safer alternatives are preferable in a woman of childbearing age, even if not pregnant.

The classification system indicating the level of safety of a particular drug during pregnancy was introduced by the US FDA.[1] All drugs are classified into the following categories:[1]
A) "Controlled studies show no risk. Adequate, well-controlled studies in pregnant women have failed to demonstrate risk to fetus".
B) "No evidence of risk in humans. Either animal findings show risk, but human findings do not; or, if no adequate human studies have been done, animal findings are negative".
C) "Risk cannot be ruled out. Human studies are lacking the animal studies are either positive for fetal risk or lacking as well. However, potential benefits may justify the potential risk".
D) "Positive evidence for risk. Investigational or post-marketing data show risk to fetus. Nevertheless, potential benefits may outweigh the potential risk".
X) "Contraindicated in pregnancy. Studies in animals or humans, or investigational or post-marketing reports, have shown fetal risk which clearly overweighs any possible benefit to the patient".

The following tables [Table - 1], [Table - 2] & [Table - 3] enumerate the FDA category of the drugs commonly prescribed by dermatologists.

While the list of drugs appears exhaustive, it is still far from complete. Moreover, adequate data is not available about the safety of many drugs.

Drugs which are absolutely contraindicated, including those agents in risk category X, should be strictly avoided. Occasionally, it may be necessary to treat a woman during pregnancy or lactation with a category C drug after weighing the pros and cons of both options and discussing them with the patient. Rarely, limited use for drugs even in category D under close supervision may be necessary.[5] Non-prescription drugs should also be avoided as far as possible. 

      References Top

1.Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of classification and information to prescribers. Drug Saf 1996;14:69-77.  Back to cited text no. 1  [PUBMED]  
2.Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol 2002;41:197-203.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Mutalik N, Salvi V. Drugs in pregnancy. In: Salvi V, editor. Medical and surgical disorders in pregnancy, Mumbai: Jaypee Brothers Medical Publishers; 2003. p. 337-413.  Back to cited text no. 3    
4.Drugs in pregnancy and breastfeeding, Created:11/17/2000 Last update: 11/30/2002 Last accessed: 20/12/2003.  Back to cited text no. 4    
5.Physician Desk References. 57th ed. Montwale NJ: Thomson PDR; 2003. p. 3054.  Back to cited text no. 5    
6.Kacew S. Fetal consequences and risks attributed to the use of prescribed and over-the-counter (OTC) preparations during pregnancy. Int J Clin Pharmacol Ther 1994;32:335-43.  Back to cited text no. 6    


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow